



SAFETY DATA SHEET

Revision date 11-Dec-2023

Version 1.01

Page 1 / 10

Section 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

1.1. Product identifier

Product Name Piperacillin and Tazobactam for Injection (Hospira, Inc.)
Product Code(s) PZ03120
Synonyms Piperacillin and Tazobactam for Injection, USP
Trade Name: Not applicable
Chemical Family: Penicillin

1.2. Relevant identified uses of the substance or mixture and uses advised against

Recommended Use Pharmaceutical product used as antibiotic agent

1.3. Details of the supplier of the safety data sheet

Hospira, A Pfizer Company
275 North Field Drive
Lake Forest, Illinois 60045
1-800-879-3477

Pfizer Ireland Pharmaceuticals
OSG Building
Ringaskiddy, Co. Cork.
Ireland
+353 21 4378701

E-mail address pfizer-MSDS@pfizer.com

1.4. Emergency telephone number

Emergency Telephone Chemtrec 1-800-424-9300 International Chemtrec (24 hours):+1-703-527-3887

Section 2: HAZARDS IDENTIFICATION

2.1. Classification of the substance or mixture

GHS - Classification: Regulated according to Regulation (EC) 1272/2008 and/or other applicable regulations.

Respiratory sensitization Category 1 - (H334)
Skin sensitization Category 1 - (H317)

2.2. Label elements

Signal word Danger

Hazard statements H334 - May cause allergy or asthma symptoms or breathing difficulties if inhaled
H317 - May cause an allergic skin reaction

SAFETY DATA SHEET

Product Name Piperacillin and Tazobactam for Injection (Hospira, Inc.)
Revision date 11-Dec-2023

Page 2 / 10
Version 1.01

Precautionary Statements

P261 - Avoid breathing dust/fume/gas/mist/vapors/spray
P285 - In case of inadequate ventilation wear respiratory protection
P271 - Use only outdoors or in a well-ventilated area
P280 - Wear protective gloves/protective clothing/eye protection/face protection
P304 + P341 - IF INHALED: If breathing is difficult, remove to fresh air and keep at rest in a position comfortable for breathing
P342 + P311 - If experiencing respiratory symptoms: Call a POISON CENTRE or doctor/physician
P302+ P352 - IF ON SKIN: Wash with plenty of soap and water
P333 + P313 - If skin irritation or rash occurs: Get medical advice/attention
P321 - Specific treatment (see supplemental first aid instructions on this label)
P363 - Wash contaminated clothing before reuse



2.3. Other hazards

Other hazards

An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

Note:

This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

Section 3: COMPOSITION/INFORMATION ON INGREDIENTS

3.1 Substances

Substances

Not applicable

3.2 Mixtures

Hazardous

Chemical name	Weight-%	REACH Registration Number	EC No	Classification according to Regulation (EC) No. 1272/2008 [CLP]	Specific concentration limit (SCL)	M-Factor	M-Factor (long-term)
Piperacillin sodium (CAS #: 59703-84-3)	89		261-868-6	Resp. Sens.1 (H334) Skin Sens.1 (H317)	Not Listed	No data available	No data available

NonHazardous

Chemical name	Weight-%	REACH Registration Number	EC No	Classification according to Regulation (EC) No. 1272/2008 [CLP]	Specific concentration limit (SCL)	M-Factor	M-Factor (long-term)
Tazobactam Sodium (CAS #:	11		Not Listed	Not classified as hazardous	Not Listed	No data available	No data available

SAFETY DATA SHEET

Product Name Piperacillin and Tazobactam for Injection (Hospira, Inc.)
Revision date 11-Dec-2023

Page 3 / 10
Version 1.01

89785-84-2)							
-------------	--	--	--	--	--	--	--

Full text of H- and EUH-phrases: see section 16

Acute Toxicity Estimate

Chemical name	Oral LD50	Dermal LD50	Inhalation LC50 - 4 hour - dust/mist - mg/L	Inhalation LC50 - 4 hour - vapor - mg/L	Inhalation LC50 - 4 hour - gas - ppm
Piperacillin sodium 59703-84-3	10000	No data available	No data available	No data available	No data available

Additional information

Non-hazardous ingredients provided for completeness. Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

Section 4: FIRST AID MEASURES

4.1. Description of first aid measures

Inhalation	Remove to fresh air. Seek immediate medical attention/advice.
Eye contact	Immediately flush eyes with water for at least 15 minutes. If irritation occurs or persists, get medical attention.
Skin contact	Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention. For information on potential delayed effects, see Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.
Ingestion	Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

4.2. Most important symptoms and effects, both acute and delayed

Most important symptoms and effects For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

4.3. Indication of any immediate medical attention and special treatment needed

Note to physicians None.

Section 5: FIRE-FIGHTING MEASURES

5.1. Extinguishing media

Suitable Extinguishing Media Use carbon dioxide, dry chemical, or water spray.

5.2. Special hazards arising from the substance or mixture

Specific hazards arising from the chemical Fine particles (such as dust and mists) may fuel fires/explosions.

Hazardous combustion products Emits toxic fumes of carbon monoxide, carbon dioxide, nitrogen oxides, sulfur oxides and other sulfur-containing compounds.

SAFETY DATA SHEET

Product Name Piperacillin and Tazobactam for Injection (Hospira, Inc.)
Revision date 11-Dec-2023

Page 4 / 10
Version 1.01

5.3. Advice for firefighters

Special protective equipment for fire-fighters Wear approved positive pressure, self-contained breathing apparatus and full protective turnout gear. Evacuate area and fight fire from a safe distance.

Section 6: ACCIDENTAL RELEASE MEASURES

6.1. Personal precautions, protective equipment and emergency procedures

Personal precautions Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

For emergency responders Use personal protection recommended in Section 8.

6.2. Environmental precautions

Environmental precautions Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

6.3. Methods and material for containment and cleaning up

Methods for containment Prevent further leakage or spillage if safe to do so.

Methods for cleaning up Avoid use of a filtered vacuum to clean spills of dry solids. Contain the source of the spill or leak. Clean spill area thoroughly. Collect spilled material by a method that controls dust generation.

Prevention of secondary hazards Clean contaminated objects and areas thoroughly observing environmental regulations.

6.4. Reference to other sections

Reference to other sections See section 8 for more information. See section 13 for more information.

Section 7: HANDLING AND STORAGE

7.1. Precautions for safe handling

Advice on safe handling

Minimize dust generation and accumulation. Avoid inhalation and contact with skin, eye, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

General hygiene considerations Handle in accordance with good industrial hygiene and safety practice.

7.2. Conditions for safe storage, including any incompatibilities

Storage Conditions Store as directed by product packaging.

7.3. Specific end use(s)

Specific use(s) Pharmaceutical drug product.

Section 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

8.1. Control parameters

Pfizer Occupational Exposure Band (OEB) Statement:

The purpose of the Occupational Exposure Band (OEB) classification system is to separate substances into different Hazard categories when the available data are sufficient to do so,

SAFETY DATA SHEET

Product Name Piperacillin and Tazobactam for Injection (Hospira, Inc.)
Revision date 11-Dec-2023

Page 5 / 10
Version 1.01

but inadequate to establish an Occupational Exposure Limit (OEL). The OEB given is based upon an analysis of all currently available data; as such, this value may be subject to revision when new information becomes available.

Piperacillin sodium

Pfizer Occupational Exposure Band (OEB):

OEB 1 - Sensitizer (control exposure to the range of 1000ug/m³ to 3000ug/m³)

Tazobactam Sodium

Pfizer Occupational Exposure Band (OEB):

OEB 1 (control exposure to the range of 1000ug/m³ to 3000ug/m³)

8.2. Exposure controls

Engineering controls

Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Environmental exposure controls

No information available.

Personal protective equipment

Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes.

Eye/face protection

Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.).

Hand protection

Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.).

Skin and body protection

Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.).

Respiratory protection

Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter). (Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10 or international equivalent.)

General hygiene considerations

Handle in accordance with good industrial hygiene and safety practice.

Section 9: PHYSICAL AND CHEMICAL PROPERTIES

9.1. Information on basic physical and chemical properties

Physical state

Powder

Color

White to off-white

Odor

No information available.

Odor threshold

No information available

Molecular formula

Mixture

Molecular weight

Mixture

Property

Values

pH

No data available

Melting point / freezing point

No data available

Boiling point / boiling range

Flash point

No information available

SAFETY DATA SHEET

Product Name Piperacillin and Tazobactam for Injection (Hospira, Inc.)
Revision date 11-Dec-2023

Page 6 / 10
Version 1.01

Evaporation rate	No data available
Flammability (solid, gas)	No data available
Flammability Limit in Air	
Upper flammability limit:	No data available
Lower flammability limit:	No data available
Vapor pressure	No data available
Vapor density	No data available
Relative density	No data available
Water solubility	No data available
Solubility(ies)	No data available
Partition coefficient	No data available
Autoignition temperature	No data available
Decomposition temperature	No data available
Kinematic viscosity	No data available
Dynamic viscosity	No data available
Particle characteristics	
Particle Size	No information available
Particle Size Distribution	No information available
Explosive properties	No information available

9.2. Other information

No information available

9.2.1. Information with regard to physical hazard classes

No information available

9.2.2. Other safety characteristics

No information available

Section 10: STABILITY AND REACTIVITY

10.1. Reactivity

Reactivity No data available.

10.2. Chemical stability

Stability Stable under normal conditions.

Explosion data

Sensitivity to Mechanical Impact No data available.

Sensitivity to Static Discharge No data available.

10.3. Possibility of hazardous reactions

Possibility of hazardous reactions No information available.

10.4. Conditions to avoid

Conditions to avoid Fine particles (such as dust and mists) may fuel fires/explosions.

10.5. Incompatible materials

Incompatible materials As a precautionary measure, keep away from strong oxidizers.

10.6. Hazardous decomposition products

Hazardous decomposition products No data available.

Section 11: TOXICOLOGICAL INFORMATION

11.1. Information on hazard classes as defined in Regulation (EC) No 1272/2008

General Information: The information included in this section describes the potential hazards of the individual

SAFETY DATA SHEET

Product Name Piperacillin and Tazobactam for Injection (Hospira, Inc.)
Revision date 11-Dec-2023

Page 7 / 10
Version 1.01

Short term	ingredients Individuals who are allergic to penicillin antibiotics could have allergic reaction, possibly severe (anaphylactic). If an allergic reaction occurs, the worker should be removed to the nearest emergency room and the appropriate therapy instituted.
Known Clinical Effects:	May cause effects similar to those seen in clinical use including transient diarrhea, nausea and abdominal pain. Individuals who are sensitive to beta lactam antibiotics, both penicillins and cephalosporins, may experience contact or systemic hypersensitivity and anaphylaxis upon exposure to this drug.
Acute toxicity	Based on available data, the classification criteria are not met.
Serious eye damage/eye irritation	Based on available data, the classification criteria are not met.
Skin corrosion/irritation	Based on available data, the classification criteria are not met.
Respiratory or skin sensitization	May cause allergy or asthma symptoms or breathing difficulties if inhaled. May cause an allergic skin reaction. Classification is based on mixture calculation methods based on component data.
STOT - single exposure	Based on available data, the classification criteria are not met.
STOT - repeated exposure	Based on available data, the classification criteria are not met.
Reproductive toxicity	Based on available data, the classification criteria are not met.
Germ cell mutagenicity	Based on available data, the classification criteria are not met.
Carcinogenicity	Based on available data, the classification criteria are not met.
Aspiration hazard	Based on available data, the classification criteria are not met.

Acute Toxicity: (Species, Route, End Point, Dose)

Piperacillin sodium

Rat Oral LD50 > 10 g/kg

Tazobactam Sodium

Mouse Oral LD50 > 5000 mg/kg

Chemical name	Oral LD50	Dermal LD50	Inhalation LC50
Piperacillin sodium	> 10 g/kg (Rat)	-	-

Acute Toxicity Comments:

A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Piperacillin sodium

Reproductive & Fertility Rat Oral 0.5 times human dose NOAEL No effects at maximum dose
Reproductive & Fertility Mouse Oral 0.5 times human dose NOAEL No effects at maximum dose
Embryo / Fetal Development Rat No route specified Dose not specified Not Teratogenic
Embryo / Fetal Development Mouse No route specified Not Teratogenic

Tazobactam Sodium

Reproductive & Fertility Rat Oral 3 times human dose NOAEL No effects at maximum dose
Embryo / Fetal Development Rat Oral 14 times human dose NOAEL Not Teratogenic, No effects at maximum dose
Embryo / Fetal Development Mouse Oral 6 times human dose NOAEL Not Teratogenic, No effects at maximum dose

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Piperacillin sodium

Bacterial Mutagenicity (Ames) *Salmonella* Negative
In Vivo Chromosome Aberration Mouse Bone Marrow Negative

Tazobactam Sodium

Bacterial Mutagenicity (Ames) *Salmonella*, *E. coli* Negative
Mammalian Cell Mutagenicity Chinese Hamster Ovary (CHO) cells Negative
In Vitro Cytogenetics Hamster Lung Cells Negative
In Vivo Chromosome Aberration Mouse Negative

Carcinogenicity

None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

SAFETY DATA SHEET

Product Name Piperacillin and Tazobactam for Injection (Hospira, Inc.)
Revision date 11-Dec-2023

Page 8 / 10
Version 1.01

11.2. Information on other hazards

11.2.1. Endocrine disrupting properties

Endocrine disrupting properties No information available.

11.2.2. Other information

Other adverse effects No information available.

Section 12: ECOLOGICAL INFORMATION

Environmental Overview: The environmental characteristics of this material have not been fully evaluated. Releases to the environment should be avoided.

12.1. Toxicity

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Tazobactam Sodium

Daphnia magna (Water Flea) LC50 48 hours > 8.5 mg/L

12.2. Persistence and degradability

Persistence and degradability No information available.

12.3. Bioaccumulative potential

Bioaccumulation No information available.

12.4. Mobility in soil

Mobility in soil No information available.

12.5. Results of PBT and vPvB assessment

PBT and vPvB assessment

Chemical name	PBT and vPvB assessment
Piperacillin sodium	The substance is not PBT / vPvB

12.6. Endocrine disrupting properties

Endocrine disrupting properties No information available.

12.7. Other adverse effects

No information available.

Section 13: DISPOSAL CONSIDERATIONS

13.1. Waste treatment methods

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural wastewater and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

SAFETY DATA SHEET

Product Name Piperacillin and Tazobactam for Injection (Hospira, Inc.)
Revision date 11-Dec-2023

Page 9 / 10
Version 1.01

Section 14: TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

UN number: Not applicable
UN proper shipping name: Not applicable
Transport hazard class(es): Not applicable
Packing group: Not applicable
Environmental Hazard(s): Not applicable

Special precautions for user: Not applicable

Section 15: REGULATORY INFORMATION

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

Piperacillin sodium

CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
EINECS	261-868-6

Tazobactam Sodium

CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
EINECS	Not Listed

European Union

Take note of Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work

Authorizations and/or restrictions on use:

This product does not contain substances subject to authorization (Regulation (EC) No. 1907/2006 (REACH), Annex XIV) This product does not contain substances subject to restriction (Regulation (EC) No. 1907/2006 (REACH), Annex XVII)

Persistent Organic Pollutants

Not applicable

Ozone-depleting substances (ODS) regulation (EC) 1005/2009

Not applicable

Legend:

TSCA - United States Toxic Substances Control Act Section 8(b) Inventory

EINECS/ELINCS - European Inventory of Existing Chemical Substances/European List of Notified Chemical Substances

AICS - Australian Inventory of Chemical Substances

SAFETY DATA SHEET

Product Name Piperacillin and Tazobactam for Injection (Hospira, Inc.)
Revision date 11-Dec-2023

Page 10 / 10
Version 1.01

15.2. Chemical safety assessment

Chemical Safety Report No information available

Section 16: OTHER INFORMATION

Key or legend to abbreviations and acronyms used in the safety data sheet

Full text of H-Statements referred to under section 3

Sensitization, skin-Cat.1; H317 - May cause an allergic skin reaction. Sensitization, respiratory-Cat.1; H334 - May cause allergy or asthma symptoms or breathing difficulties if inhaled.

Data Sources: Pfizer proprietary drug development information. Publicly available toxicity information.

Reason for revision Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking. Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 11 - Toxicology Information. Updated Section 12 - Ecological Information. Updated Section 15 - Regulatory Information.

Revision date 11-Dec-2023

Prepared By Pfizer Global Environment, Health, and Safety

Pfizer Inc believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.